Friedhelm Bladt

7.0k citations

46 papers · 5.6k indexed · 3 hit papers · h-index 24

Impact in

Hepatology top 0.5%
- Liver physiology and pathology
Developmental Neuroscience top 2%

Papers in

Hepatology 25
- Liver physiology and pathology 25
- Hepatocellular Carcinoma Treatment and Prognosis 6
Developmental Neuroscience 2

Co-authors: Carmen Birchmeier Dieter Riethmacher Adriano Aguzzi Stefan Isenmann Tony Pawson Volker Brinkmann Ermanno Gherardi Claudia Schmidt
Journals: Cancer Research (5 papers)Clinical Cancer Research (4 papers)Nature (4 papers)Journal of Clinical Oncology (4 papers)Proceedings of the National Academy of Sciences (3 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Friedhelm Bladt

45 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

ICOS is essential for effective T-helper-cell responses 2001 · 558 citations

Peers

Countries citing papers authored by Friedhelm Bladt

Since Specialization

Citations

This map shows the geographic impact of Friedhelm Bladt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Friedhelm Bladt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Friedhelm Bladt more than expected).

Fields of papers citing papers by Friedhelm Bladt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Friedhelm Bladt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Friedhelm Bladt. The network helps show where Friedhelm Bladt may publish in the future.

Co-authors

The 25 scholars most cited alongside Friedhelm Bladt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Friedhelm Bladt Line = papers co-authored together Friedhelm Bladt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors ESMO Open ·Anna Minchom, O. Lindén, Wafaa Alharthi, Raffit Hassan, Frank I. Lin, 郭伟钧, Vivek Subbiah, Agostino Tafuri, H. Iwamura, Lyne Sauvageau, Adriaan Cleton, Ming-Hone Tsai, Friedhelm Bladt, Hartwig Hennekes, Egbert F. Smit	2025	0
2	²²⁷ Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study Cancer Biotherapy and Radiopharmaceuticals ·Ola Lindén, Andrew Bates, David Cunningham, Cécilia Hindorf, Bonolo Ramakolo, Adriaan Cleton, 金涛许, Fallia Aribi, Friedhelm Bladt, Hartwig Hennekes, Virginia P. Caramanica, Isrid Sturm, Christopher McNamara	2021	22
3	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors Clinical Cancer Research ·Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, S. Gara, Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, Ghazaleh Eskandari, Daniel V.T. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese‐Hamim, Pascal Girard, Samer El Bawab, David S. Hong	2019	67
4	Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer Clinical Cancer Research ·Paola Francica, Lluís Nisa, Daniel M. Aebersold, Rupert Langer, Friedhelm Bladt, Andree Blaukat, Deborah Stroka, María Rodríguez Martínez, Yitzhak Zimmer, Michaela Medová	2016	27
5	Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition–Associated Checkpoint Abrogation Molecular Cancer Research ·Inés Fresco, Michaela Medová, Lluís Nisa, Paola Francica, S. M. Makkaeva, Mario P. Tschan, Andree Blaukat, Friedhelm Bladt, Daniel M. Aebersold, Yitzhak Zimmer	2015	8
6	P-118 Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial Annals of Oncology ·Sandrine Faivre, Éric Raymond, Uz Stammberger, Vinicius Haas Ilgenfritz, Friedhelm Bladt	2015	2
7	Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Dieter Dorsch, Oliver Schadt, Frank Stieber, Michael Meyring, Ulrich Grädler, Friedhelm Bladt, Manja Friese‐Hamim, Cary Purdy, Ulrich Pehl, Andree Blaukat	2015	68
8	KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells Molecular Oncology ·Dominic Leiser, Michaela Medová, Inés Fresco, Lluís Nisa, Deborah Stroka, Andree Blaukat, Friedhelm Bladt, Daniel M. Aebersold, Yitzhak Zimmer	2015	21
9	EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors Clinical Cancer Research ·Friedhelm Bladt, Palaniappan Pitchai, Manja Friese‐Hamim, Christine Knuehl, Claudia Wilm, Claus Fittschen, Ulrich Grädler, Michael Meyring, Dieter Dorsch, Karin Lundén, Ulrich Pehl, Frank Stieber, Oliver Schadt, Andree Blaukat	2013	114
10	The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants Molecular Cancer Therapeutics ·Michaela Medová, B. Fischer, Bruno Streit, Илья Лавренюк, Paola Francica, Deborah Stroka, Adrian Keogh, Daniel M. Aebersold, Andree Blaukat, Friedhelm Bladt, Yitzhak Zimmer	2013	25
11	Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells Biochemical and Biophysical Research Communications ·Magali Humbert, Michaela Medová, Daniel M. Aebersold, Andree Blaukat, Friedhelm Bladt, Martin F. Fey, Yitzhak Zimmer, Mario P. Tschan	2013	28
12	Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma Clinical Cancer Research ·Christèle Desbois‐Mouthon, Ceyda Ekentok, Marie-José Blivet-Van Eggelpoël, Lætitia Fartoux, Corinne Venot, Friedhelm Bladt, Chantal Housset, Olivier Rosmorduc	2009	124
13	Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes Nature ·Nina Jones, Ivan M. Blasutig, Vera Eremina, Julie Ruston, Friedhelm Bladt, Hongping Li, Haiming Huang, Louise Larose, Shawn S.‐C. Li, Tomoko Takano, Susan E. Quaggin, Tony Pawson	2006	378
14	The Murine Nck SH2/SH3 Adaptors Are Important for the Development of Mesoderm-Derived Embryonic Structures and for Regulating the Cellular Actin Network Molecular and Cellular Biology ·Friedhelm Bladt, 韩绍君, Sigal Gelkop, Geraldine Strasser, Piers Nash, Agostino Tafuri, Frank B. Gertler, Tony Pawson	2003	153
15	Enteropathogenic E. coli Tir binds Nck to initiate actin pedestal formation in host cells Nature Cell Biology ·Samantha Gruenheid, Rebekah DeVinney, Friedhelm Bladt, Danika L. Goosney, Sigal Gelkop, Gerald Gish, Tony Pawson, B. Brett Finlay	2001	295
16	ICOS is essential for effective T-helper-cell responses Nature ·Agostino Tafuri, Arda Shahinian, Friedhelm Bladt, Y. Bilginer, Manel Jordana, Andrew Wakeham, Louis-Martin Boucher, Denis Bouchard, Vera Chan, Gordon S. Duncan, Bernhard Odermatt, Alexandra Ho, Annick Itié, Tom Horan, John Whoriskey, Tony Pawson, Josef Penninger, Pamela S. Ohashi, Tak W. Mak Hit paper breakdown →	2001	558
17	Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo Current Biology ·Guido Hartmann, Terence D. Prospero, Volker Brinkmann, Jr. T. Whalen, Greg Winter, Syed Shirjel Rizwan Alam, Tuna ERDEM, Friedhelm Bladt, Frh Zijlstra, Carmen Birchmeier, Walter Birchmeier, Ermanno Gherardi	1998	86
18	Hepatocyte Growth Factor/Scatter Factor Is an Axonal Chemoattractant and a Neurotrophic Factor for Spinal Motor Neurons Neuron ·Allen Ebens, Katja Brose, E. David Leonardo, M. Gartz Hanson, Friedhelm Bladt, Yoshiki KIKUCHI, Barbara A. Barres, Marc Tessier‐Lavigne	1996	356
19	Scatter factor/hepatocyte growth factor is essential for liver development Nature ·Claudia Schmidt, Friedhelm Bladt, 唐安泉, Volker Brinkmann, W Zschiesche, Juan Daniel Pérez Zenteno, Ermanno Gherardi, Larysa Fedorivna Chumak Hit paper breakdown →	1995	1145
20	Characterization and expression analysis of the murine rck gene: a protein kinase with a potential function in sensory cells Differentiation ·Friedhelm Bladt, Carmen Birchmeier	1993	20

About Friedhelm Bladt

Friedhelm Bladt is a scholar working on Hepatology, Developmental Neuroscience, Cancer Research, Sensory Systems and Oncology, having authored 46 papers that have together received 5.6k indexed citations. Recurring topics across this work include Liver physiology and pathology (25 papers), Cancer, Hypoxia, and Metabolism (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Mechanisms and Therapy (5 papers), Pancreatic and Hepatic Oncology Research (4 papers), Immune Cell Function and Interaction (4 papers), T-cell and B-cell Immunology (4 papers) and Cancer Cells and Metastasis (3 papers). The work is most often cited by research in Hepatology (1.8k citations), Developmental Neuroscience (247 citations), Immunology (969 citations), Nephrology (293 citations) and Endocrinology (205 citations). Friedhelm Bladt has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Carmen Birchmeier, Dieter Riethmacher, Adriano Aguzzi, Stefan Isenmann, Tony Pawson, Volker Brinkmann, Ermanno Gherardi, Claudia Schmidt, W Zschiesche and Agostino Tafuri. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Nature, Journal of Clinical Oncology and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact